Polling Questions

< All Questions
According to the webcast:

With Leonard R Derogatis, PhD
In two Phase 3 clinical studies in premenopausal women with hypoactive sexual desire disorder (HSDD), bremelanotide:
 Confirmed a statistically significant, clinically meaningful increase in desire, and decrease in distress compared with placebo at 24 weeks
 Confirmed improvements in other components of sexual functioning, arousal, lubrication, and orgasm
 Produced ratings of overall satisfaction and treatment benefits that were significantly better than those of placebo
 All of the above

Your answers are confidential and will be used for educational purposes only.